Prehypertension and the cardiometabolic syndrome: is there any value in pharmacologic intervention?
The potential benefit of drug therapy for prehypertension and the cardiometabolic syndrome has previously not been confirmed. This case represents a patient who may show slowing or avoiding progression from prehypertension to hypertension based on recent trial evidence and assists the clinician in identifying the risk associated with blood pressure elevation before a conventional cut point of 140/90 mm Hg.